PACE™ models to demonstrate economic value in a policy context
The definition of ‘value’ is increasingly broad and holistic. Policymakers and payers want to understand the real impact of an intervention on clinical practice, outside of controlled environments such as clinical trials. We recognise that there is a gap between clinical practice and what is actually captured by traditional budget impact or cost-effectiveness models and so have developed the Policy, Affordability and Cost-Effectiveness (PACE™) model to bring HE modelling into the modern reimbursement landscape.
With an understanding that reimbursement decisions are based on many different criteria and that it is rarely a ‘head-to-head’ decision, the PACE™ model helps you to demonstrate the impact of your product on the market. Unlike generating a traditional ICER, the Adelphi Values PACE model™ compares your product to the entire market, not just a single comparator in the same indication.
Broader scope than traditional cost-effectiveness models, with a weighted ICER to take into account market share displacement
Joint probability of cost-effectiveness and affordability
Able to assess multiple policy scenarios relating to patient access
Able to demonstrate the wider clinical and economic impact of bringing a new product to market on an entire patient population
Click here to view a conference poster detailing our PACE™ model
Multi-comparator ICER – A new framework for cost-effectiveness analysis
Health Economics & Data Analysis
Click here for details of our wider expertise and our database of published research and conference presentations
